A Study in Subjects With Retinal Detachment

Merck Sharp & Dohme (MSD)

Status and phase

Completed

Phase 1

Conditions

Retinal Detachment

Treatments

Drug: denufosol tetrasodium (INS37217) Intravitreal Injection

Study type

Interventional

Funder types

Industry

Identifiers

NCT00210067

06-101

Details and patient eligibility

About

The purpose of this trial is to access the tolerability of INS37217 Intravitreal Injection when administered intravitreally in subjects with macula-on or macula-off rhegmatogenous retinal detachment (RRD).

Enrollment

14 patients

Sex

Volunteers

No Healthy Volunteers

Inclusion criteria

have macula-on or macula-off rhegmatogenous retinal detachment
are eligible for pneumatic retinopexy, with identifiable retinal breaks
are phakic or pseudo-phakic

Exclusion criteria

have detachments not of a rhegmatogenous nature
currently have blood in the vitreous, corneal opacity, or other conditions which limit the view of peripheral retina
have evidence of intraocular inflammation (uveitis)
have a history of current condition of uncontrollable, elevated IOP or open-angle glaucoma
have breaks not conducive to a single procedure of pneumatic retinopexy treatment
have proliferative vitreoretinopathy of type C or D
have previously had a vitrectomy or require one
have previously had a scleral buckle procedure